Aurorus / Initiatives / 63&9
63&9 Global Coalition for NCD Reduction

Saving 1.5 million lives by 2036.

Every year, 17 million people die prematurely from preventable disease — parents, workers, and community leaders cut down decades before they should be. UN Sustainable Development Goal 3.4 commits the world to reducing this by one-third. The world is not on track. Aurorus is proud to be one of the founding partners of 63&9, the global coalition built to close that gap.

63% of adults assessed in covered jurisdictions
9% reduction in premature NCD mortality in covered populations
1.5M lives saved worldwide by 2036
A clinician assesses a child in a rural village using a handheld Aurorus device
One assessment, anywhere — no needles, no lab, under seven minutes
§ 02
The gap

Non-communicable diseases — cardiovascular disease, diabetes, cancer, chronic respiratory illness — now account for the majority of premature deaths worldwide. Most are preventable, and most are detectable years before they turn fatal.

The barrier has never been the medicine. It has been reaching people early enough, often enough, and cheaply enough to change the outcome — at the scale of entire populations rather than the few who reach a clinic in time.

The reality The world is not on track to meet the UN's goal of cutting premature NCD deaths by one-third by 2030
The response 63&9 unites governments, non-profits, businesses, and researchers in a coalition built to close the gap
§ 03
How it works

Assess. Intervene. Measure.

63&9 uses a clinically validated, FDA-cleared handheld device to assess individuals in under seven minutes. The device is battery-powered, requires no needles or consumables, and is deployable in hospitals, clinics, or in the field. Every assessment is held under sovereign-grade data governance and ends with a personalized care pathway — pharmaceutical, primary care, lifestyle, functional medicine, or food-as-medicine — matched to the risk profile of each patient.

01 · Assess

Population-scale baseline

Cost-effective screening across entire regions. The patient owns the data, the country retains residency, and an independent Data Trust serves as custodian.

02 · Intervene

The right care pathway

Each result is routed to the appropriate pathway. Multi-modal interventions — pharmaceutical, lifestyle, dietary, and behavioral — are co-deployed and equally resourced.

03 · Measure

Objective outcomes

Pre- and post-intervention reassessment produces objective outcomes. Results are published in peer-reviewed literature and an annual public Scorecard.

§ 04
Phased rollout

Seven regional chapters, one coalition.

A phased global rollout — launching in founding flagships, expanding to seven chapters, then scaling within every region.

Explore the 63&9 Initiative →

Phase 1 · 2026–2032 Launch Founding flagships

Founding Flagships launch across the Americas and Caribbean: Costa Rica, Grenada, Barbados, Vermont, Toronto + Ottawa, Yucatán.

~14M
Adults in launch population
Phase 2 · 2028–2034 Expand Five new chapters

Five additional regional chapters launch: 63&9 Pacific, Africa, South America, Europe, and Asia. All seven chapters operational by 2034.

~340M
Adults in flagship population
Phase 3 · 2032–2036 Scale Within-region growth

Within-region expansion across every chapter. Coverage extends to additional jurisdictions, populations, and care settings worldwide.

~580M
Adults covered globally
Outcome · By 2036 Deliver Lasting infrastructure

A regional NCD surveillance and routing infrastructure that did not previously exist — a platform that continues scaling toward 7.5M+ lives saved by 2045.

1,500,000
Lives saved worldwide
§ 05
The economics

Among the most efficient interventions in global health.

$3.16B
Total investment over 10 years
~$2,107
Per life saved
At this cost-effectiveness, 63&9 ranks alongside the most efficient global health interventions — directly comparable to vaccine campaigns and tobacco control policy.
§ 06
The technology

How Aurorus unlocks this at scale.

The instrument is the model. 63&9 isn't a program that happens to use a device — its entire economics, reach, and accountability rest on what Aurorus makes possible: assessing anyone, anywhere, repeatedly, affordably.

No needle, no lab

A single non-invasive scan replaces phlebotomy, consumables, and lab turnaround. No cold chain, no reagents — a community health worker can run it where no laboratory exists.

Seven minutes, battery-powered

Under seven minutes per assessment, on a device that runs without mains power. That throughput is what makes screening entire regions — not just clinic visitors — economically feasible.

One scan, many systems

A read across 49 physiological channels triages the full NCD spectrum — cardiometabolic, inflammatory, respiratory — from a single assessment rather than a battery of separate tests.

Objective & comparable

Every result is quantitative, archivable, and comparable across providers and populations. Pre/post reassessment is what produces the Scorecard and the peer-reviewed evidence base.

Sovereign-grade governance

The patient owns the data; the country retains residency; an independent Data Trust holds custody. This is what lets governments deploy at national scale with confidence.

Cleared & validated

FDA De Novo cleared, with peer-reviewed performance across coronary artery disease, diabetes, and metabolic syndrome. Credible enough to serve as public-health infrastructure.

§ 07
Go deeper

Learn how Aurorus works.

Dive deeper into the technology to see how Aurorus can provide fast, non-invasive assessments at scale.

Explore how it works →
Systems Dashboard
Aurorus Systems Dashboard: the body's major systems scored and color-coded green, yellow, or red
§ 08
Get involved

Founding partners, across every sector.

63&9 is seeking founding partners to launch the coalition. Each role is defined; each stakeholder contributes.

01Governments
02Multilateral institutions
03Health systems
04Industry
05Academia
06Philanthropy

Each role is defined; each stakeholder contributes — no single partner controls.

Become a founding partner →
Clinical evidence

FDA De Novo cleared (2016) as a new electrophysiological measurement tool. Peer-reviewed performance: AUC 0.93 coronary artery disease · 0.953 metabolic syndrome. Independent clinical oversight by NAMSA; FDA submission directed by former FDA Deputy Director Phil Phillips.

Methodology & contact

Cost-per-life-saved derived from a four-channel stacked-impact model (direct screening-to-treatment, behavioral, policy, and care-pathway effects). Full methodology available on request. The 63&9 Fund at Haven Charitable · barret@havencharitable.org